Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Shionogi Inc. Announces FDA Approval of CUVPOSAâ„¢ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions

July 29, 2010 By Bio-Medicine.Org

FLORHAM PARK, N.J., July 29 /PRNewswire/ — Shionogi Inc., a
U.S.-based group company of Shionogi & Co., Ltd., today
announced the U.S. Food and Drug Administration approval of
CUVPOSA™ (glycopyrrolate), the first liquid treatment for
patients ages 3-16 who suffer from chronic severe drooling
associated with neurologic conditions such as cerebral palsy.
CUVPOSA™ was designated an Orphan Drug by the FDA.

“The FDA approval of CUVPOSA provides parents and caregivers the
first liquid medication indicated to reduce chronic severe
drooling,” said Donald C. Manning,
MD, PhD, Chief Medical Officer of Shionogi Inc. “Shionogi is proud
to bring to market a product that treats an all-too-often
unresolved yet damaging condition.”

Cerebral palsy is a lifelong condition that encompasses a group
of non-progressive, neurological disorders affecting body movement
and muscle coordination. According to previous estimates from a
study reported by the CDC, the national prevalence of CP is
approximately 0.2% in children including 17 year olds. About 10-30
percent of children with CP suffer from excessive drooling, which
can lead to various health issues such as skin irritation as well
as a decreased quality of life.

CUVPOSA™ is a competitive inhibitor of acetylcholine
receptors that are located on certain peripheral tissues, including
salivary glands. CUVPOSA™ indirectly reduces the rate
of salivation by preventing stimulation of these receptors.
CUVPOSA™ is available as a 1mg/5ml clear, cherry flavored
oral solution.

This approval is based on the results of a randomized,
double-blind, placebo-controlled Phase III study which showed that
75% of children and adolescents treated with CUVPOSA™
experienced an

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech